By Blake Brittain WASHINGTON -Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking ...

Andrew Witty—who also said that 'the health system needs to function better'— made his comments during an earnings call ...

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris ...

The FDA authorized the marketing of 20 Zyn products on Thursday, marking the first allowance for the fast-growing nicotine ...

Aurinia's Lupkynis showed inconsistent revenues and losses at first, but 2024 saw a turnaround with significant revenue ...

Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' ...

Sources predict required front-of-pack labeling could mean giving up key real estate in costly redesigns — or, more ...